Clinical Trials

80 enrolled

Phase 1 Active not recruiting

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT03478462 2026-03-18

CLOVER-2

30 enrolled

CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT03502733 2026-03-18

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase 1 Active not recruiting

64 enrolled

Lymphoma, Neoplasm Metastasis

NCT04301076 2026-03-18

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

30 enrolled

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04439201 2026-03-18

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

40 enrolled 9 charts

Lymphoma, Hematologic Neoplasms

NCT04439292 2026-03-18

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

35 enrolled

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439318 2026-03-18

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

50 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439331 2026-03-18

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-03-18

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04904588 2026-03-18

ACCESS

LymphoidMyeloidOther hematologic neoplasmOther neoplasm

300 enrolled

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05490771 2026-03-18

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT06303167 2026-03-18

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

19 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06308822 2026-03-18

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

35 enrolled 9 charts

Lymphoma, Multiple Myeloma

NCT06400238 2026-03-18

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT06390826 2026-03-17

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

10 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT06390839 2026-03-17

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

43 enrolled 10 charts

Lymphoma

NCT06859424 2026-03-17

ACCELERATE

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

358 enrolled

Anemia, Refractory, with Excess of Blasts, Lymphoma, Myeloproliferative Disorders, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT07476378 2026-03-17

Archonc-001

Phase NA Not yet recruiting

69 enrolled

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00006721 2026-03-16

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Phase 3 Completed

571 enrolled 12 charts

Lymphoma, Lymphoma, Follicular

NCT02332668 2026-03-16

MK-3475-051

Phase 1/2 Recruiting

370 enrolled

DermatologicLymphoid

Lymphoma, Melanoma

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Phase 1/2 Recruiting

160 enrolled

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05131022 2026-03-16

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Phase 1 Recruiting

572 enrolled

Phase EARLY_PHASE1 Recruiting

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05294367 2026-03-16

Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma

60 enrolled

Lymphoma

NCT07137494 2026-03-16

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Phase 1 Recruiting

12 enrolled

Lymphoma, Recurrence

NCT07221500 2026-03-16

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

100 enrolled

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07472972 2026-03-16

Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

Recruiting

50 enrolled

Lymphoma, Recurrence

NCT02808780 2026-03-13

OPAL

Active not recruiting

537 enrolled

Colitis, Ulcerative, Lymphoma, Neoplasms

NCT06510309 2026-03-13

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

33 enrolled

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT06510361 2026-03-13

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

35 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT06875063 2026-03-13

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Phase 1 Recruiting

45 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT05332054 2026-03-12

LTFS

Enrolling by invitation

150 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT05442515 2026-03-12

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Phase 1/2 Recruiting

126 enrolled